Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'An open-label, multi-center, phase I/Ib study of IEV407 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2- negative breast cancer'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National University Hospital
Trial Status: NA
Principal Investigator(s):
Dr Lee Soo Chin
Published by HT Digital Content Services with permission from Health Daily Digest....